Device Trial Radar · NCT07940036
Skin Cancer Detection in Primary Care With and Without DermaSensor
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- DermaSensor, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized controlled trial evaluates whether primary care physician access to the DermaSensor device increases the proportion of patients with histopathology-confirmed skin cancer compared with physician standard clinical assessment alone. Participating physicians are randomized and outcomes are drawn from existing electronic health record data for up to 500,000 patient encounters.
Conditions
- Skin Cancer
- Basal Cell Cancer
- Squamous Cell Carcinoma
- Melanoma (Skin Cancer)
- Melanoma In Situ
- Melanoma Detection
- Melanoma
Interventions
DermaSensorDevice
Handheld device used by primary care physicians as an adjunct to clinical assessment of skin lesions suggestive of skin cancer, per its labeling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with histopathology-confirmed skin cancerTime frame: Within 12 months of the initial primary care visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SSM Health
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.